Prognostic significance of plasma SDF-1 in acute ischemic stroke patients with diabetes mellitus: the CATIS trial
Authors' conclusion
Elevated plasma SDF-1 was significantly associated with an increased risk of recurrent stroke and cardiovascular events only in ischemic patients with diabetes mellitus.
Study context
- Population
- Acute ischemic stroke patients with a baseline plasma SDF-1 measurement, CATIS trial (China)
- Participants
- 3,255 patients
- Comparison
- Higher vs lower plasma SDF-1 levels
- Primary endpoint
- Recurrent stroke, cardiovascular events and all-cause mortality
- Follow-up
- One year
Methodological detailsmulticenter
- Multicenter
Primary result
As reported in the abstract
Recurrent stroke, cardiovascular events and all-cause mortality by plasma SDF-1 level
- Higher plasma SDF-1 levels were not associated with recurrent stroke, cardiovascular events and all-cause mortality
- all P trend ≥ 0.05
Further findings
| Outcome | Estimate | |
|---|---|---|
| Patients with DM: per 1-SD higher log-SDF-1 · one year1-SD higher log-SDF-1 · adjusted for confounders | HR, recurrent stroke 1.65 (95% CI 1.18–2.32) | |
| Patients with DM: per 1-SD higher log-SDF-1 · one year1-SD higher log-SDF-1 · adjusted for confounders | HR, cardiovascular events 1.47 (95% CI 1.08–1.99) | |
| Patients with DM: per 1-SD higher log-SDF-1 · one year1-SD higher log-SDF-1 | HR, all-cause mortality 1.36 (95% CI 0.96–1.93) | |
| 0.512Ratio (log scale) |
Interaction of SDF-1 with history of DM · one year
- Interaction on recurrent stroke
- P = 0.005
- Interaction on cardiovascular events
- P = 0.007
- Interaction on all-cause mortality
- P = 0.04
Patients without DM · one year
- No associations between plasma SDF-1 and clinical outcomes
- all P > 0.05
Risk prediction
- Adding SDF-1 to conventional risk factors model significantly improved risk prediction of all outcomes
Two-year outcomes · two years
- Associations of elevated SDF-1 with outcomes found only in patients with DM
Original publication
Prognostic significance of plasma SDF-1 in acute ischemic stroke patients with diabetes mellitus: the CATIS trial. Cardiovasc Diabetol. Published 10 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →